[PDF] Top 20 Rev. Bras. Hematol. Hemoter. vol.35 número2
Has 10000 "Rev. Bras. Hematol. Hemoter. vol.35 número2" found on our website. Below are the top 20 most common "Rev. Bras. Hematol. Hemoter. vol.35 número2".
Rev. Bras. Hematol. Hemoter. vol.35 número2
... 4. de Souza CA, Pagnano KB, Bendit I, Conchon M, Freitas CM, Coelho AM, Funke VA, Bernardo WM. Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.35 número2
... PFS: progression-free survival; OS: overall survival; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CR: complete remission; RR: response rate; CMML: chronic myelomonoc[r] ... See full document
8
Rev. Bras. Hematol. Hemoter. vol.35 número2
... 5. Silva AC, Pereira RC, Cliquet MG. Frequencia de anemia e características hematimétricas em pacientes idosos atendidos no ambulatório de Geriatria da Faculdade de Ciências Médicas e da Saúde da PUCSP [Abstract 114]. ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.35 número2
... This is the irst case reported of pancreatoblastoma that was treated with autologous hematopoietic stem cell transplantation as irst line treatment without radiotherapy at the site of t[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.35 número2
... Here, we report a case of Hb Southampton (also known as Hb Casper) (b106 Leu → Pro, CTG → CCG) in a women who was diagnosed for the irst time at age 37 and referred to our laboratory w[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.35 número2
... Despite the evidence of the beneicial effect of this treatment, Brazilian health authorities, based on an opinion of a member of the National Research Ethics Committees (Com[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.35 número2
... 11. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, ... See full document
10
Rev. Bras. Hematol. Hemoter. vol.35 número2
... Simultaneously, the inlammatory process promotes the mobilization of fatty acids from the cell membrane to produce lipid mediators, which also participate of the inlammatory response[r] ... See full document
7
Rev. Bras. Hematol. Hemoter. vol.35 número2
... The hematological parameters analyzed in the blood samples included the hemoglobin concentration, mean cell volume (MCV), mean corpuscular hemoglobin concentration (MCHC) and red cell [r] ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.35 número2
... Conclusion : Apparently these are the irst cases of hemoglobin Ottawa, St Luke’s, Etobicoke and the α212 gene described in Brazil. The hemoglobins detected in this study may lead to fal[r] ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.35 número2
... Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance.. Vin[r] ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.35 número2
... Background: The Kell blood group system expresses high and low frequency antigens with the most important in relation to transfusion including the antithetic KEL1 and KEL2; KEL3 and KEL[r] ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.35 número2
... For the microbiological analyses, two 25 g aliquots of each sample were separated. One aliquot was diluted in 225 mL of saline solution (0.85% sodium chloride, Synth), homogenized in a microbiology sample blender ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.35 número2
... Conclusion: The health care of sickle cell anemia patients should take into account not only the clinical aspects of the disease, but also psychosocial aspects by providing counseling [r] ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.35 número2
... 14. Kimura EM, Oliveira DM, Jorge SE, Abreu CF, Albuquerque DM, Costa FF, et al. Identiicação e caracterização de variantes novas e raras da hemoglobina humana. Rev Bras Hematol Hemoter. ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.35 número2
... 3. Rezende VM, Rivellis AJ, Gomes MM, Dörr FA, Novaes MM, Nardinelli L, et al. Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.35 número2
... of the molecular basis for most red cell antigens in recent years allows the use of molecular assays to determine the presence or absence of alleles for various blood groups (genotype) [r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.35 número6
... Our results show that neither the severity of the illness (ECOG performance scale, Karnofsky scale, presence of metastasis and BMI) nor inlammatory background (CRP) can predict [r] ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.35 número6
... In an effort to reduce alloimmunization, some programs have been designed and implemented to provide Rh and K antigen-matched RBC transfusions to patients who are in need of chronic tr[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.35 número6
... 14. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, ... See full document
6
temas relacionados